Strong early U.S. YORVIPATH® launch with 908 prescriptions as of Feb. 7, 2025; YORVIPATH full year 2024 revenue of €28.7 million - Following pre-NDA meeting with FDA, on track to submit TransCon CNP ...
Jenburkt Pharmaceuticals Limited, a 40-year-old pharmaceutical organization listed on the Bombay Stock Exchange and a pioneer ...
The pharmaceutical landscape is undergoing a dramatic transformation. New modalities are reshaping what's possible in drug development, from monoclonal antibodies to RNA therapies, from small ...
Health scientists and drug industry executives around the world are on alert after the confirmation of Robert F. Kennedy Jr., who spreads antivaccine misinformation and has often derided the ...
As the technology industry continues its shift towards AI dominance, an important schism is opening up that threatens to ...
Alliance Ground International, one of the three largest North American airport logistics providers for air cargo transport, ...
As the demand for novel therapies and personalized medicine surges, leaders are uniquely positioned to create a culture of creativity, collaboration and innovation.
Pharmaceutical company Takeda is pioneering a technology-enabled, patient-centered future for plasma-derived therapies ...
As the Q4 2024 pharma earnings period rolls on through the first month of President Donald Trump’s second term, executives ...
We have already seen the first wave of AI-powered dangers. Deepfakes, bot accounts, and algorithmic manipulation on social ...
FDA slaps China-based API makers with separate warning letters outlining quality, testing shortfalls
A pair of Chinese manufacturers with active pharmaceutical ingredients that were previously shipped to the U.S. | The FDA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback